DHIVY
Peakcarbidopa levodopa
NDAORALTABLET
Approved
Nov 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
5/8 — Partial
DHIVY (carbidopa levodopa) is dopa decarboxylase inhibitors [moa]. First approved in 2021.
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DHIVY is an oral tablet formulation of carbidopa/levodopa, a combination that inhibits DOPA decarboxylase to enhance dopamine availability in the central nervous system. It is indicated for Parkinson's disease and related movement disorders where dopamine replacement is therapeutically needed. The drug works by preventing peripheral metabolism of levodopa, allowing more of the active compound to reach the brain.
$0.995MPart D
Peak12.7 years to LOEProduct is in peak revenue phase with modest Part D penetration, suggesting a mature market with stable but limited growth opportunities for commercial expansion.
Mechanism of Action
DOPA Decarboxylase Inhibitors
Pharmacologic Class:
Aromatic Amino Acid Decarboxylation Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DHIVY offers stable, mature-product experience in a high-burden indication (Parkinson's disease) with an established patient base and reimbursement infrastructure. This is a consolidation-stage role best suited for professionals seeking deep commercial expertise in neurology rather than launch-phase innovation or pipeline advancement.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.